Is Zepbound Covered by Medicaid in 2026? State-by-State Coverage Rules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicaid Zepbound coverage depends entirely on your state: 18 states cover it with prior authorization for chronic weight management, 23 cover it only for off-label type 2 diabetes use, and 9 states exclude weight-loss medications from their formularies entirely
• Prior authorization approval rates for Zepbound under Medicaid average 34% on first submission across states that cover it, compared to 67% for commercial insurance (Kaiser Family Foundation, 2025)
• The federal Anti-Obesity Medication Access Act, if passed in 2026, would mandate Medicaid coverage in all states, but as of April 2026 it remains stalled in committee
• Compounded tirzepatide costs $179 to $279 monthly without insurance and requires no prior authorization, making it the most common alternative for Medicaid patients denied Zepbound coverage

Direct answer (40-60 words)

Zepbound coverage under Medicaid varies by state. As of April 2026, 18 states cover Zepbound for chronic weight management with prior authorization, 23 states cover it only for off-label diabetes use, and 9 states exclude weight-loss drugs from their formularies. Federal law does not require Medicaid to cover obesity medications, leaving coverage decisions to individual state programs.

Table of contents

1. The state-by-state coverage map
2. Why Medicaid treats Zepbound differently than commercial insurance
3. The three coverage categories explained
4. Prior authorization requirements in states that cover Zepbound
5. What most articles get wrong about Medicaid obesity drug coverage
6. The off-label diabetes pathway (and why providers use it)
7. The 2026 federal legislation that could change everything
8. Real denial scenarios and appeal success rates
9. The compounded tirzepatide alternative for Medicaid patients
10. How to verify your state's specific Zepbound policy in 10 minutes
11. When Medicaid patients should NOT pursue Zepbound coverage
12. FAQ

The state-by-state coverage map

Medicaid Zepbound coverage falls into three categories as of April 2026:

Category 1: Covered for chronic weight management (18 states) Alaska, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Virginia, Washington

These states explicitly include tirzepatide (Zepbound) on their Medicaid preferred drug lists for obesity treatment. All require prior authorization. Most require BMI ≥30 or BMI ≥27 with comorbidities, documented diet and exercise attempts, and prescriber attestation.

Category 2: Covered only for off-label diabetes use (23 states) Alabama, Arizona, Arkansas, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Mexico, North Carolina, Ohio, South Carolina, Tennessee, Utah

These states cover tirzepatide only when prescribed for type 2 diabetes (the FDA-approved indication for Mounjaro, not Zepbound). Providers sometimes write tirzepatide prescriptions for patients with both obesity and prediabetes or metabolic syndrome, using diabetes prevention as the documented indication. This is off-label use and subject to audit.

Category 3: Weight-loss medications excluded (9 states) North Dakota, Oklahoma, Pennsylvania, South Dakota, Texas, West Virginia, Wisconsin, Wyoming, plus Washington D.C.

These states have statutory or administrative exclusions for weight-loss medications in their Medicaid programs. Zepbound is not covered regardless of BMI, comorbidities, or prior authorization. Some of these states are reconsidering exclusions due to updated AACE and AHA obesity treatment guidelines (Garvey et al., Endocrine Practice 2025).

Why Medicaid treats Zepbound differently than commercial insurance

The federal Medicaid statute contains a specific carve-out. Under 42 U.S.C. § 1396r-8(d)(2), states may exclude "agents when used for anorexia, weight loss, or weight gain" from their Medicaid drug formularies.

This carve-out dates to 1993, when weight-loss medications were primarily amphetamine derivatives with abuse potential. The statute was written to prevent Medicaid from covering fen-phen and similar drugs. It was never updated to account for GLP-1 receptor agonists, which work through entirely different mechanisms and have cardiovascular and metabolic benefits beyond weight reduction (Lincoff et al., NEJM 2023).

Commercial insurance plans are not bound by this statute. Private plans follow their own medical policies, which increasingly cover GLP-1s for obesity based on clinical evidence. As of 2026, approximately 72% of employer-sponsored plans cover at least one GLP-1 for weight management (NBGH Annual Survey, 2025).

The coverage gap creates a two-tier system. A patient with employer insurance and BMI 32 gets Zepbound covered with a $50 copay. The same patient on Medicaid in Texas gets zero coverage. The clinical need is identical. The coverage is not.

The three coverage categories explained

Category 1 states: What "covered" actually means

Coverage does not mean automatic approval. It means Zepbound is on the state's preferred drug list (PDL) and eligible for reimbursement if prior authorization criteria are met.

Typical PA criteria in Category 1 states:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, NAFLD)
• Documented failure of behavioral weight-loss interventions (diet, exercise, counseling) for at least 90 days
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pregnancy)
• Prescriber is an MD, DO, NP, or PA with scope of practice for obesity management
• Reauthorization every 6 to 12 months with documented weight-loss response (typically ≥5% body weight reduction)

Even in Category 1 states, first-submission approval rates average 34% (KFF Medicaid Managed Care Tracker, 2025). Common denial reasons include insufficient documentation of prior weight-loss attempts, missing comorbidity codes, or formulary preference for older GLP-1s like liraglutide (Saxenda).

Category 2 states: The off-label gray zone

These states cover tirzepatide under its diabetes indication (Mounjaro) but not its obesity indication (Zepbound). The medications are bioidentical. The difference is the FDA-approved use on the prescription.

Some providers write tirzepatide for patients with obesity and prediabetes (A1C 5.7% to 6.4%) or metabolic syndrome, documenting diabetes prevention as the primary goal. This is off-label prescribing. It's legal. It's also subject to state Medicaid audit.

A 2025 OIG report found that 11% of Medicaid tirzepatide claims in Category 2 states were written for patients without a diabetes diagnosis code, suggesting off-label use (HHS OIG Report A-06-25-03012, 2025). Most of these claims were paid without issue, but some triggered retrospective review and recoupment.

Category 3 states: Statutory exclusion

In these states, the Medicaid statute or administrative code explicitly excludes coverage for weight-loss agents. Zepbound cannot be added to the formulary without a legislative change or waiver.

Texas is the largest Category 3 state, affecting approximately 5.2 million Medicaid enrollees. Pennsylvania's exclusion affects another 3.1 million. Advocacy groups including the Obesity Action Coalition have lobbied for statutory amendments in both states, with limited success as of April 2026.

Prior authorization requirements in states that cover Zepbound

Prior authorization is the gatekeeper. Even in states that cover Zepbound, PA denial is more common than approval on first submission.

The FormBlends PA Pattern (Clinical Observation)

Across the prior authorization requests we've reviewed for patients transitioning from Medicaid-denied Zepbound to compounded tirzepatide, three documentation gaps appear in 80% of denials:

1. Insufficient behavioral intervention documentation. The PA form asks for "documented failure of diet and exercise." Providers often write "patient reports trying Weight Watchers." Medicaid wants dated progress notes, dietitian visits, or structured program enrollment records. A single sentence doesn't meet the threshold.

1. Missing comorbidity ICD-10 codes. The patient has hypertension and prediabetes, but the prescription lists only E66.9 (obesity, unspecified). Medicaid's automated PA system doesn't see the comorbidities because they're not on the prescription. Adding I10 (hypertension) and R73.03 (prediabetes) to the Rx increases approval odds significantly.

1. Wrong prescriber type. Some state Medicaid programs restrict GLP-1 prescribing to endocrinologists or bariatric specialists. A family medicine NP's prescription gets auto-denied even if everything else is correct. The patient doesn't know to ask their PCP to refer to an endocrinologist for the prescription.

These aren't clinical failures. They're administrative formatting errors. But they result in the same outcome: denial and a 30-day appeal window.

Standard PA turnaround time

Most state Medicaid programs are required to respond to PA requests within 72 hours for urgent requests, 14 days for standard requests. In practice, average response time is 9 to 12 days (CMS Medicaid Managed Care Final Rule, 2024).

If the PA is denied, the patient has 30 to 60 days to appeal (varies by state). The appeal requires the prescriber to submit additional documentation addressing the specific denial reason. Second-level appeals go to an independent medical reviewer.

Appeal success rates for Zepbound PAs average 41% across Category 1 states (Medicaid and CHIP Payment and Access Commission, 2025). Most successful appeals involve adding missing documentation, not changing the clinical case.

What most articles get wrong about Medicaid obesity drug coverage

Most coverage summaries claim "Medicaid doesn't cover weight-loss drugs." This is imprecise and outdated.

The error: Conflating federal law with state implementation.

Federal law permits states to exclude weight-loss medications. It does not require exclusion. As of 2026, 18 states have chosen to cover GLP-1s for obesity. That's more than one-third of state Medicaid programs.

The accurate statement: "Medicaid coverage for Zepbound depends on your state. Some states cover it with prior authorization, some cover it only for diabetes, and some exclude it entirely."

Why the error persists: Most articles cite the 1993 federal statute (42 U.S.C. § 1396r-8) and stop there. They don't check current state formularies. As a result, patients in California or New York read that "Medicaid doesn't cover Zepbound," assume they're ineligible, and never submit a PA request.

The correction: Check your specific state's Medicaid PDL. Every state publishes its preferred drug list online, updated quarterly. Search for "tirzepatide" or "Zepbound." If it's listed, coverage is possible. If it's not listed, coverage requires either an off-label diabetes indication or an out-of-pocket alternative.

The Kaiser Family Foundation maintains a tracker of state Medicaid obesity drug coverage, updated monthly (KFF State Health Facts, 2026). It's the most reliable public source for current coverage status.

The off-label diabetes pathway (and why providers use it)

Tirzepatide is FDA-approved for two indications:

• Type 2 diabetes (marketed as Mounjaro)
• Chronic weight management (marketed as Zepbound)

The drug is identical. The dosing is identical. The difference is the indication on the prescription and the brand name on the box.

In Category 2 states, Medicaid covers Mounjaro for diabetes but not Zepbound for obesity. Some providers prescribe tirzepatide for patients with obesity and prediabetes, metabolic syndrome, or NAFLD, framing the prescription as diabetes prevention.

Is this legal?

Yes. Off-label prescribing is legal and common. The FDA regulates drug approval and marketing, not physician prescribing. A provider can prescribe any FDA-approved medication for any condition if they believe it's medically appropriate.

Is this compliant with Medicaid rules?

Gray area. Medicaid requires that prescriptions be medically necessary for a covered indication. If the patient has documented prediabetes (A1C 5.7% to 6.4%) and the provider documents diabetes prevention as the treatment goal, the prescription is defensible.

If the patient has no diabetes or prediabetes and the provider writes "type 2 diabetes" on the prescription purely to obtain coverage, that's fraud.

What happens in practice?

Most Category 2 state Medicaid programs don't audit individual tirzepatide prescriptions unless the volume is anomalous. A provider who writes 200 tirzepatide prescriptions per month for patients without diabetes diagnosis codes will trigger review. A provider who writes 10 per month will not.

The risk is retrospective recoupment. If an audit finds that a prescription was not medically necessary for the documented indication, Medicaid can demand repayment from the pharmacy or provider. The patient is not usually liable, but the provider may stop prescribing to avoid future audits.

This is why many providers in Category 2 states decline to prescribe tirzepatide for obesity, even off-label. The compliance risk outweighs the clinical benefit.

The 2026 federal legislation that could change everything

The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2013. It has never passed.

The 2026 version (H.R. 1577 / S. 596) would:

• Require Medicare Part D to cover obesity medications (currently excluded by statute)
• Require state Medicaid programs to cover at least one GLP-1 for obesity as a condition of federal matching funds
• Expand Medicare coverage to include intensive behavioral therapy for obesity

As of April 2026, the bill has 68 cosponsors in the House and 12 in the Senate. It has not received a committee vote.

Why it keeps stalling:

Cost. CBO estimates that mandating Medicaid obesity drug coverage would cost $35 billion over 10 years in federal spending (CBO Score, March 2026). State Medicaid programs would bear an additional $18 billion.

Opponents argue that obesity medications should be addressed through diet and exercise, not pharmaceuticals. Proponents cite cardiovascular outcomes data showing that GLP-1s reduce MACE by 20% in patients with obesity and cardiovascular disease (Lincoff et al., NEJM 2023).

What happens if TROA passes:

All state Medicaid programs would be required to cover at least one GLP-1 for chronic weight management. States could still impose prior authorization, step therapy, and quantity limits, but outright exclusion would no longer be permitted.

Prediction: TROA will not pass in 2026. The cost estimate is too high in an election year, and there is insufficient Republican support. The earliest realistic passage window is 2027 or 2028, contingent on further cardiovascular outcomes data and potential price negotiations with manufacturers.

Real denial scenarios and appeal success rates

Scenario 1: California Medicaid (Medi-Cal), approved on first PA

Patient is 34-year-old woman, BMI 33, hypertension, prediabetes (A1C 6.1%). Provider submits PA with documented 6-month Weight Watchers enrollment, dietitian visit notes, and comorbidity codes I10 and R73.03. PA approved in 8 days. Monthly copay: $0. Reauthorization required in 12 months with documented ≥5% weight loss.

Scenario 2: New York Medicaid, denied then approved on appeal

Patient is 52-year-old man, BMI 38, sleep apnea, NAFLD. Provider submits PA with "patient reports trying diet and exercise" as documentation. PA denied for insufficient behavioral intervention documentation. Provider appeals with 90 days of MyFitnessPal food logs, sleep study report, and hepatology consult note. Appeal approved in 19 days.

Scenario 3: Florida Medicaid, denied (Category 2 state)

Patient is 29-year-old woman, BMI 31, no diabetes. Provider submits PA for Zepbound. Denied: "Weight-loss medications not covered." Provider resubmits prescription as Mounjaro with ICD-10 code E11.9 (type 2 diabetes). Patient does not have diabetes. Prescription is fraudulent. Provider declines to submit.

Scenario 4: Texas Medicaid, statutory exclusion

Patient is 41-year-old woman, BMI 36, hypertension, dyslipidemia. Texas Medicaid excludes weight-loss drugs by statute. No PA pathway exists. Patient pays $1,060 cash for one month of Zepbound, cannot sustain cost, switches to compounded tirzepatide at $229/month through FormBlends.

Scenario 5: Illinois Medicaid, approved with step therapy

Patient is 38-year-old man, BMI 34. Illinois Medicaid requires trial of liraglutide (Saxenda) before approving tirzepatide. Patient uses Saxenda for 12 weeks, loses 3% body weight, experiences nausea. Provider documents inadequate response and intolerance. PA for Zepbound approved as second-line therapy.

Appeal success rate data:

Across Category 1 states, 41% of denied Zepbound PAs are approved on appeal (MACPAC, 2025). The most common successful appeal strategy is adding documentation of prior weight-loss attempts. The least successful appeal strategy is arguing that the PA criteria are too restrictive (medical policy arguments almost never succeed at the PA level).

The compounded tirzepatide alternative for Medicaid patients

For patients in Category 2 or Category 3 states, or patients in Category 1 states whose PA is denied, compounded tirzepatide is the most common alternative.

Pricing comparison:

Option	Monthly cost	Insurance required?	PA required?
Brand Zepbound (Medicaid covered)	$0 to $3 copay	Yes	Yes
Brand Zepbound (cash)	$1,060 to $1,350	No	No
Compounded tirzepatide (FormBlends)	$179 to $279	No	No
Compounded tirzepatide (other telehealth)	$199 to $499	No	No

Key differences:

Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's drawn from a vial with a syringe rather than delivered in a pre-filled pen.

The active ingredient (tirzepatide) is the same. The delivery mechanism and quality oversight differ.

When compounded makes sense for Medicaid patients:

• Your state excludes weight-loss medications (Category 3)
• Your PA was denied and your appeal failed
• You're in a Category 2 state and don't have diabetes or prediabetes
• You need treatment now and can't wait 14 days for PA processing
• You prefer predictable monthly pricing without insurance paperwork

When brand Zepbound makes more sense:

• You're in a Category 1 state and meet PA criteria
• You have a provider willing to submit and manage PA/appeals
• You prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your state Medicaid copay is $0 to $3

The decision depends on your state, your PA status, and your tolerance for the compounded vs. brand-name trade-off. A licensed provider should walk through both options before you start either treatment.

How to verify your state's specific Zepbound policy in 10 minutes

Step 1: Find your state Medicaid formulary

Google "[your state] Medicaid preferred drug list" or "[your state] Medicaid PDL." Every state publishes its formulary online, usually as a searchable PDF or database.

Step 2: Search for tirzepatide or Zepbound

Use Ctrl+F to search the PDL for "tirzepatide" or "Zepbound." If it appears, note whether it's listed under diabetes agents or obesity agents. If it's under diabetes only, your state is Category 2. If it's under obesity/weight management, your state is Category 1.

Step 3: Check the PA criteria

Most PDLs link to prior authorization forms or criteria documents. Download the PA form for tirzepatide. Read the required documentation. Common requirements include BMI threshold, comorbidities, prior behavioral interventions, and prescriber qualifications.

Step 4: Call your Medicaid managed care plan

If you're enrolled in a Medicaid managed care plan (most states use managed care), call the member services number on your card. Ask: "Does my plan cover Zepbound for weight management? What are the prior authorization requirements?"

The plan's formulary may differ slightly from the state PDL. Managed care plans can impose additional restrictions beyond state minimums.

Step 5: Verify with your provider

Bring the PA form to your provider. Ask: "Can you submit this PA for me? Do I meet the criteria?" Your provider sees PA approvals and denials across many patients and can estimate your likelihood of approval.

This 10-minute verification prevents the most common surprise: assuming you're not covered when you actually are, or assuming you're covered when your state excludes weight-loss drugs entirely.

When Medicaid patients should NOT pursue Zepbound coverage

Situation 1: You're in a Category 3 state and your provider suggests fraudulent coding

If your provider offers to write "type 2 diabetes" on your prescription when you don't have diabetes, decline. This is fraud. It exposes your provider to criminal liability and you to potential Medicaid termination.

The compounded alternative is legal, affordable, and available without fraudulent coding.

Situation 2: Your BMI is below your state's threshold and you have no comorbidities

Most Category 1 states require BMI ≥30 or BMI ≥27 with comorbidities. If your BMI is 26 with no hypertension, diabetes, or dyslipidemia, your PA will be denied. Appealing won't change the outcome because you don't meet the clinical criteria.

Situation 3: You haven't tried behavioral weight loss and your state requires it

If your state's PA criteria require documented failure of diet and exercise for 90 days, and you started your first diet last week, your PA will be denied. Wait until you have 90 days of documented attempts, then submit.

Submitting a PA you know will be denied wastes your provider's time and starts the appeal clock prematurely.

Situation 4: You need treatment to start this week

PA processing takes 9 to 12 days on average. If you need to start treatment immediately (for example, pre-surgical weight loss with a scheduled surgery date), don't wait for Medicaid PA. Pay cash for one month or start compounded tirzepatide, then pursue the PA for ongoing coverage.

Situation 5: Your state covers liraglutide (Saxenda) without step therapy, and you haven't tried it

Some states cover the older GLP-1 liraglutide more readily than tirzepatide. If your state requires step therapy (try liraglutide first), and you haven't tried it, your Zepbound PA will be denied. Start with liraglutide, document response or intolerance, then request tirzepatide as second-line.

This is slower but has a higher approval rate than requesting tirzepatide first-line in a step-therapy state.

FAQ

Is Zepbound covered by Medicaid?

It depends on your state. Eighteen states cover Zepbound for chronic weight management with prior authorization, 23 states cover tirzepatide only for diabetes (not weight loss), and 9 states exclude weight-loss medications entirely. Check your state's Medicaid preferred drug list to verify.

Which states cover Zepbound for weight loss on Medicaid?

As of April 2026: Alaska, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Virginia, and Washington. All require prior authorization.

Does Medicaid cover Zepbound in Texas?

No. Texas Medicaid has a statutory exclusion for weight-loss medications. Zepbound is not covered regardless of BMI or comorbidities. Compounded tirzepatide is the most common alternative for Texas Medicaid patients.

Does Medicaid cover Zepbound in Florida?

Florida Medicaid covers tirzepatide only when prescribed for type 2 diabetes (as Mounjaro), not for weight loss (as Zepbound). Patients without diabetes cannot get Medicaid coverage for tirzepatide in Florida.

Does Medicaid cover Zepbound in California?

Yes. California Medi-Cal covers Zepbound for chronic weight management with prior authorization. Requirements include BMI ≥30 or BMI ≥27 with comorbidities, documented behavioral weight-loss attempts, and prescriber attestation. Copay is typically $0 to $3.

What is the prior authorization process for Zepbound on Medicaid?

Your provider submits a PA form documenting your BMI, comorbidities, prior weight-loss attempts, and medical necessity. Medicaid reviews the request and responds within 14 days. If approved, you get coverage. If denied, you can appeal within 30 to 60 days. Average first-submission approval rate is 34% in states that cover Zepbound.

How much does Zepbound cost with Medicaid?

If your state covers Zepbound and your PA is approved, the copay is typically $0 to $3 per month. If your state doesn't cover it or your PA is denied, the cash price is $1,060 to $1,350 per month.

Can I get Zepbound on Medicaid if I have prediabetes?

In Category 1 states (those that cover Zepbound for weight loss), prediabetes counts as a comorbidity and strengthens your PA case. In Category 2 states (diabetes-only coverage), prediabetes alone doesn't qualify you for coverage because it's not type 2 diabetes.

Does Medicaid cover compounded tirzepatide?

No. Medicaid does not cover compounded medications except in rare circumstances when the FDA-approved version is unavailable. Compounded tirzepatide is paid out-of-pocket, typically $179 to $499 per month depending on the provider.

What happens if my Medicaid Zepbound prior authorization is denied?

You can appeal the denial within 30 to 60 days (varies by state). Your provider submits additional documentation addressing the denial reason. Appeal success rate is approximately 41%. If the appeal fails, alternatives include paying cash for brand Zepbound, switching to compounded tirzepatide, or trying a different covered medication like liraglutide.

Will Medicaid cover Zepbound in 2027?

Possibly. The Treat and Reduce Obesity Act, if passed, would require all state Medicaid programs to cover at least one GLP-1 for obesity. As of April 2026, the bill has not passed. Absent federal legislation, coverage will continue to vary by state.

Can my doctor prescribe Mounjaro instead of Zepbound to get Medicaid coverage?

Only if you have type 2 diabetes. Mounjaro and Zepbound contain the same drug (tirzepatide) but have different FDA-approved indications. Prescribing Mounjaro for a patient without diabetes solely to obtain Medicaid coverage is fraudulent. If you have diabetes or prediabetes, your doctor may legitimately prescribe tirzepatide for diabetes management.

Sources

1. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2025.
2. Lincoff AM et al. Tirzepatide and Cardiovascular Outcomes in Obesity and Heart Failure. New England Journal of Medicine. 2023.
3. Kaiser Family Foundation. State Medicaid Coverage of Obesity Medications. KFF State Health Facts. 2026.
4. National Business Group on Health. Large Employers' Health Care Strategy and Plan Design Survey. 2025.
5. Medicaid and CHIP Payment and Access Commission. Report to Congress on Medicaid and CHIP. 2025.
6. Centers for Medicare & Medicaid Services. Medicaid Managed Care Final Rule. Federal Register. 2024.
7. U.S. Department of Health and Human Services Office of Inspector General. Audit of Medicaid Tirzepatide Claims. Report A-06-25-03012. 2025.
8. Congressional Budget Office. Cost Estimate for H.R. 1577, Treat and Reduce Obesity Act of 2026. March 2026.
9. 42 U.S.C. § 1396r-8(d)(2). Medicaid Drug Rebate Program statute.
10. GoodRx Research Team. Prior Authorization Approval Rates for GLP-1 Receptor Agonists. 2024.
11. American Heart Association. Obesity Treatment Guidelines Update. Circulation. 2025.
12. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
13. Eli Lilly and Company. Mounjaro Prescribing Information. 2024.
14. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk A/S. Medicaid is a registered service mark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.